Public Company

CohBar, Inc.


CohBar is a clinical-stage biotechnology company focusing on developing breakthrough therapeutics targeting chronic and age-related diseases with minimal or no current treatment options by leveraging the power of the mitochondria and its encoded peptides within its genome. With an expert team of scientists in mitochondrial biology, broad IP coverage, key opinion leaders and a disciplined drug discovery and development process, CohBar has become a leader in exploring the mitochondrial genome and its utility for development of novel therapeutics.


Founded 2007
Type Public
Location Pasadena, California, USA Menlo Park, California, USA


CWBR $1.70 -2.30% $(0.04)

Latest News

CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022 Oct 26, 2022 GlobeNewswire Inc. Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock? Oct 21, 2022 Zacks Investment Research Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong...
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday Sep 26, 2022 Benzinga Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday. Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares climbed 46.4%...
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session Sep 23, 2022 Benzinga Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq...
CohBar Announces Reverse Stock Split Sep 22, 2022 GlobeNewswire Inc. MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and...